- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 11 | SEC Filings | ||
| 10.09. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.09. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update | 320 | PR Newswire | A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patient receives two doses of INT230-6 eight days apart, followed... ► Artikel lesen | |
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 20.08. | Benchmark lowers Intensity Therapeutics stock price target to $1.50 on dilution | 3 | Investing.com | ||
| 12.08. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Brookline Capital upgrades Intensity Therapeutics stock rating to Buy | 3 | Investing.com | ||
| 12.08. | Intensity Therapeutics regains compliance with Nasdaq requirement | 2 | Seeking Alpha | ||
| 12.08. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement | 168 | PR Newswire | SHELTON, Conn., Aug. 12, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology... ► Artikel lesen | |
| 08.08. | Intensity Therapeutics GAAP EPS of -$0.13 | 1 | Seeking Alpha | ||
| 07.08. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 97 | PR Newswire | Over $11 million raised since the beginning of 2Q 2025
Cash runway extended into the second half of 2026
In the INVINCIBLE-4 Study, patients receiving INT230-6... ► Artikel lesen | |
| 07.08. | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.08. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 04.08. | Intensity Therapeutics raises $6.6M via at-the-market offering | 2 | Seeking Alpha | ||
| 18.07. | Intensity Therapeutics: Aktionäre bestätigen Direktor und Wirtschaftsprüfer | 2 | Investing.com Deutsch | ||
| 18.07. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.06. | Intensity Therapeutics: INT230-6 Achieves Complete Responses In Murine Models Of MPNST | 1 | RTTNews | ||
| 30.06. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST) | 171 | PR Newswire | SHELTON, Conn., June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology... ► Artikel lesen | |
| 27.06. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.06. | Intensity Therapeutics shares plummet on proposed public offering | 3 | Seeking Alpha | ||
| 11.06. | Intensity Therapeutics kündigt öffentliches Angebot von Stammaktien an | 3 | Investing.com Deutsch |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,95 | +0,17 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| NOVAVAX | 7,343 | +0,30 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 58,00 | -0,85 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| EDITAS MEDICINE | 3,106 | -2,76 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GINKGO BIOWORKS | 11,600 | -0,85 % | Dr. Dennis Riedl: Diese Aktie hat es in sich: Riedls Biotech-Wette auf zelluläre Landwirtschaft | ||
| NOVOCURE | 11,810 | 0,00 % | Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress | Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in Prague... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,051 | 0,00 % | XFRA 473A: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILADAPTH.TH.SP.ADR6... ► Artikel lesen | |
| ADVERUM BIOTECHNOLOGIES | 3,860 | +1,05 % | Eli Lilly To Acquire Adverum Biotechnologies In Deal Worth Up To $12.47 Per Share | INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) on Friday said it has agreed to acquire Adverum Biotechnologies, Inc. (ADVM) in a transaction valued at up to $12.47 per share.Under the... ► Artikel lesen | |
| NUVALENT | 93,39 | +2,75 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| QIAGEN | 42,405 | +0,32 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 66,06 | -3,25 % | Tarsus Pharmaceuticals stock price target raised to $88 from $72 at H.C. Wainwright | ||
| INHIBRX BIOSCIENCES | 57,29 | +102,01 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 6,260 | +55,34 % | Morning Market Movers: AlphaVest Acquisition Corp., Neuphoria Therapeutics, BranchOut Food, rYojbaba See Big Swings | BEIJING (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARVINAS | 9,210 | +0,66 % | Arvinas reports promising preclinical data for KRAS G12D cancer drug | ||
| RECURSION PHARMACEUTICALS | 6,040 | +5,59 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,238 Euro und damit -1,41 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.